36 F. Supp. 3d 320
S.D.N.Y.2014Background
- Lead Plaintiff sues Delcath Systems and CEO Hobbs under Section 10(b)/Rule 10b‑5 for misleading disclosures about the Melblez Kit.
- Delcath’s Melblez Kit is a hepatic-chemosaturation device; Phase III data showed significant toxicity and mortality.
- The FDA reviewed NDA submissions, with a later Gen 2 filter proposed in 2012; FDA briefing documents revealed high SAE/mortality in Phase III.
- Defendants allegedly failed to disclose that SAEs were higher in the Drug Group and that no deaths occurred in the Control Group.
- ODAC/CFDA concerns followed public statements praising data; stock declined after adverse disclosures and the Complete Response Letter.
- Court grants in part and denies in part the Motion to Dismiss; the Phase III Results Statements and certain omissions survive for §10(b) liability.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Phase III results sufficiently misleading? | Alleged omissions about SAEs and mortality misled investors. | Disclosures were not false; data subject to interpretation. | Phase III omissions stated plausibly actionable. |
| FDA Approval Statements actionable? | Statements about FDA approval were misleading. | Forward‑looking with cautionary language; not actionable. | FDA Approval Statements not actionable. |
| Scienter established? | Defendants knew or had access to contrary data. | No concrete personal benefit proven; weak inference. | Strong inference of scienter supported. |
| Loss causation pleaded? | Price dropped after FDA/ODAC disclosures revealing risk. | Causation tied to FDA denial, not misstatements. | Loss causation adequately pleaded. |
| Section 20(a) control person liability? | Control persons liable for primary violation. | If primary claim fails, derivative liability fails. | Section 20(a) claim survives. |
Key Cases Cited
- Matrixx Initiatives, Inc. v. Siracusano, 131 S. Ct. 1309 (U.S. 2011) (materiality focuses on total mix but not every adverse event disclosure)
- Ashcroft v. Iqbal, 556 U.S. 662 (U.S. 2009) (plausibility pleading standard)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (U.S. 2007) ( Rule 8 pleading standard; no formulaic recitation of elements)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (U.S. 2007) (reasonable inference standard for scienter)
- ATSI Commc’ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (2d Cir. 2007) (definitive pleading requirements for securities fraud under PSLRA)
- Kleinman v. Elan Corp., 706 F.3d 145 (2d Cir. 2013) (context of disclosures and materiality in pharmaceutical data)
- Halperin v. eBanker USA.com, Inc., 295 F.3d 352 (2d Cir. 2002) (safe harbor and cautionary language evaluate materiality of forward‑looking statements)
- Novak v. Kasaks, 216 F.3d 300 (2d Cir. 2000) (strong inference of scienter from facts showing access to contrary information)
- In re AstraZeneca Sec. Litig., 559 F. Supp. 2d 453 (S.D.N.Y. 2009) (recklessness/scienter in pharmaceutical data cases)
- In re Pfizer Inc. Securities Litig., 584 F. Supp. 2d 621 (S.D.N.Y. 2008) (scienter established by knowledge of adverse results)